Cell expansion system for use in neural transplantation

Details Cell expansion system for use in neural transplantation Cell expansion system for use in neural transplantation

2001-03-16

2004-09-07

Mickelvey, Terry (Department: 1636)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S325000, C435S384000, C424S093210, C514S04400A

Reexamination Certificate

active

06787356

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to the use of differentiated cells in the treatment of neurodegenerative disorders.
BACKGROUND OF THE INVENTION
Parkinson's disease is a neurodegenerative disorder affecting an estimated one million patients in the United States. Several strategies are being pursued to develop new therapies for Parkinsonian patients. These techniques range from the use of dopaminotrophic factors (Takayama et al., (1995)
Nature Med
. 1, 53-58) and viral vectors (Choi-Lundberg et al., (1997)
Science
275, 838-841) to the transplantation of primary xenogeneic tissue (Deacon et al., (1997)
Nature Med
. 3, 350-353). Fetal nigral transplantation is a clinically promising experimental treatment in late stage Parkinson's disease. More than 200 patients have been transplanted worldwide and clinical improvement was confirmed (Olanow et al. (1996)
Trends Neurosci
. 19, 102-109 and Wenning et al., (1997)
Ann.Neurol
. 42, 95-107) and was correlated to good graft survival and innervation of the host striatum in post mortem studies of transplanted patients (Kordower et al., (1995)
N.Engl.J.Med
. 332, 1118-1124).
Cell transplantation usually involves transplanting primary cells or immortalized cells into a patient. There has been mixed success in clinical trials where primary cells have been utilized. It is believed that the inadequate supply of primary cells or use of different proportions of primary cell types cause many trials to fail or to give inconsistent results.
Furthermore, neural transplantation remains a controversial procedure. Current transplantation treatment involves the use of material derived from at least 3-5 embryos to obtain a clinically reliable improvement in the patient. This poses an enormous logistical and ethical dilemma.
For these reasons, much effort has been devoted to finding alternatives to fetal tissue for use in transplantation. Although use of neural stem cells is promising because stem cells can be proliferated prior to differentiation, such stem cells have a relatively low proportion (about 0.1%) dopaminergic neurons. Since the clinical efficacy of transplants is in large part dependent upon the number of dopaminergic cells transplanted, finding a method to increase the proportion of dopaminergic cells in a CNS stem cell culture would have obvious clinical benefits. Additionally, successful numerical expansion of primary CNS precursors could alleviate some of the ethical and technical difficulties involved in the use of human fetal tissue. There is thus a need for a process that will provide sufficient viable cells for a reliable, effective clinical cell transplantation.


REFERENCES:
patent: 5218094 (1993-06-01), della Valle
patent: RE35653 (1997-11-01), Aebischer et al.
patent: 5750103 (1998-05-01), Cherksey
patent: 5753491 (1998-05-01), Major et al.
patent: 5792900 (1998-08-01), Lee et al.
patent: 5853385 (1998-12-01), Emerich et al.
patent: 5869463 (1999-02-01), Major et al.
patent: 5874301 (1999-02-01), Keller et al.
patent: WO 91/09936 (1991-07-01), None
patent: WO 94/10292 (1994-05-01), None
patent: WO 94/16718 (1994-08-01), None
patent: WO 96/15224 (1996-05-01), None
Verma et al (1997) Nature 389:239-242.*
Palu et al (1999) J. Biotechnol. 68: 1-13.*
Fox, ASM News, Feb. 2000, 66 (2): 1-3.*
Deloulme et al (1991) J. Neuroscience Research 29:499-509.*
Björkland (2000) Neural transplantation in neurodegenerative disease. Wiley, Chichester (Novartis Foundation Symposium) p. 7-20.*
Svendsen et al (1999) TINS 22:357-364.*
Bohler et al (1999) Cells Tissues Organs 165:237-245.*
Buc-Caron (1995) Neurobiology of Disease 2:37-47.*
Eldridge et al (1987) Journal of Cell Biology 105:1023-1034.*
Debeir et al., Neuroscience, 1998, vol. 82, No. 3, pp. 739-752.*
Studer, L., “Culture of Substantia Nigra Neurons”,Current Protocols in Neuroscience, vol. 1, Unit 3.3, pp. 3.3.1-3.3.12 (1997).
Bottenstein et al. “Growth of a Rat Neuroblastoma Cell Line in Serum-Free Supplemental Medium”,Proc. Nat'l. Acad. Sci.,USA 75 (1979): pp. 514-517.
Studer, L. et al. “Transplantation of in Vitro Expanded and Reaggregated Mesencephalic Precursors to Behavioral Recovery in 60HDA Lesioned Rats,”Society for Neuroscience abstracts, vol. 23, No. 1-2 (1997): pp. 1998. XP000870279.
Strecker et al. “Survival and Function of Aggregate Cultures of Rat Fetal Dopamine Neurons Grafted in a Rat Model of Parkinson's Disease,” Exp. Brian Res., vol. 76, No. 3 (1989): pp. 315-22. XP000867471.
Studer et al. “Transplantation of Expanded Mesencephalic Precursors Leads to Recovery in Parkinsonian Rats”,Nat. Neurosci., vol. 1, No. 4 (Aug. 1998): pp. 290-295. XP000870304.
Reynolds et al. “Generation of Neurons and Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous System”,Science, vol. 255 (Mar. 27, 1992): pp. 1707-1710.
Arsenijevic et al. “Insulin-Like Growth Factor-I Is a Differentiation Factor for Postmitotic CNS Stem Cell-Derived Neuronal Precursors: Distinct Actions from Those of Brain-Derived Neurotrophic Factor”,The Journal of Neuroscience, vol. 18, No. 6 (Mar. 15, 1998): pp. 2118-2128.
Johe et l. “Single Factors Direct the Differentiation of Stem Cells from the Fetal and Adult Central Nervous System,”Genes&Development, vol. 10 (1996): pp. 3129-3140.
Honegger et al. “Growth and Differentiation of Segregating Fetal Brian Cells in a Serum—Free Defined Medium”,Nature, vol. 282 (Nov. 15, 1979): pp. 305-308.
Björklund, A. et al., “Cell replacement therapies for central nervous system disorders”,nature neuroscience, vol. 3, No. 6, pp. 537-544 (Jun. 2000).
Clarkson, Edward D., et al., “Development of Fetal Neural Transplantation as a Treatment for Parkinson's Disease”,Life Science, vol. 65, No. 23, pp. 2427-2437 (1999).
Olanow, C.W., et al. “Fetal nigral transplantation as a therapy for Parkinson's disease”,trends in Neurosciences, vol. 19, No. 3, pp. 102-109 (1996).
Wartiovaara, K., “Gene Therapy Approaches to Neurodegenerative Disease”,Neural Notes, vol. V, Issue 3, pp. 5-8, (2000).
Dambly-Chaudiere et al., “The bHLH genes in neural development,”Int. J. Dev. Biol., 42:269-273 (1998).
Skeath, J. et al., “Theachaete-scutecomplex proneural genes contribute to neural precursor specification in theDrosophilaCNS,”Current Biology, 6(9):1146-1152 (1996).

Affiliated with

Also associated with

Rating

Cell expansion system for use in neural transplantation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell expansion system for use in neural transplantation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell expansion system for use in neural transplantation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3188651